Anzeige
❌
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A2P9YT | ISIN: ES0169501022 | Ticker-Symbol: PMRA
Tradegate
24.04.24
20:09 Uhr
28,620 Euro
+0,180
+0,63 %
Branche
Biotechnologie
Aktienmarkt
IBEX MEDIUM CAP
1-Jahres-Chart
PHARMA MAR SA Chart 1 Jahr
5-Tage-Chart
PHARMA MAR SA 5-Tage-Chart
RealtimeGeldBriefZeit
28,60029,12019:03
28,70028,98019:03

Aktuelle News zur PHARMAMAR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiPHARMA MAR, S.A.: The Company files first quarter 2024 financial information.2CNMV
DiPHARMA MAR, S.A.: The Company announces the call of the Ordinary General Shareholders' Meeting and submits proposed resolutions.2CNMV
08.04.PHARMA MAR, S.A.: EthiFinance Ratings maintains long-term credit rating of Pharma Mar.2CNMV
05.04.PHARMA MAR, S.A.: The Company reports details of the operations of the Liquidity Agreement between 01/02/2024 and 31/03/20241CNMV
04.04.PHARMA MAR, S.A.: The Executive Committee of Pharma Mar, S.A. has decided to implement the Stock Ownership Plan approved by resolution of the General Shareholders' Meeting of 31 May 2023.2CNMV
28.02.PHARMA MAR, S.A.: The Company reports draw up of the Annual Financial Statements 2023, a proposal for a dividend, and a conference call with analysts and investors.8CNMV
28.02.PHARMA MAR, S.A.: The Company sends press release regarding year 2023 results together with financial report.7CNMV
28.02.PHARMA MAR, S.A.: FY2023 release of results6CNMV
31.01.PHARMA MAR, S.A.: The Company reports on treasury share acquisitions in the period from January 1 to January 31, 2024. Ending of the Acquisition of Treasury Shares and resumption of the liquidity contract.4CNMV
30.01.PHARMA MAR, S.A.: The Company informs of changes in the chairmanship of the Appointments and Compensation and Sustainability Committee.3CNMV
08.01.PHARMA MAR, S.A.: The Company reports on treasury share acquisitions in the period from December 1 to December 31, 2023.2CNMV
18.12.23PHARMA MAR, S.A.: Sylentis, a subsidiary of Pharma Mar, announces that the FYDES study to evaluate the safety of tivanisiran in patients with dry eye disease has met its primary endpoint.9CNMV
12.12.23PHARMA MAR, S.A.: The Company announces that its partner Luye Pharma Group Ltd has received approval for commercialization for Zepzelca® (lurbinectedina) in Hong Kong.9CNMV
05.12.23PHARMA MAR, S.A.: The Company reports on treasury share acquisitions in the period from November 1 to November 30, 2023.2CNMV
04.12.23PHARMA MAR, S.A.: The Company announces that its partner Luye Pharma Group Ltd has received approval for commercialization for Zepzelca® (lurbinectedina) in Macao.7CNMV
07.11.23PHARMA MAR, S.A.: The Company announces that its partner Adium Pharma has received approval for commercialization for Zepzelca® (lurbinectedina) in Peru.7CNMV
06.11.23PHARMA MAR, S.A.: The Company reports on treasury share acquisitions in the period from October 1 to October 31, 20234CNMV
06.11.23PHARMA MAR, S.A.: The Company announces a US$10 million milestone payment from Janssen Products LP10CNMV
31.10.23PHARMA MAR, S.A.: Pharma Mar initiates a Phase IIb/III clinical trial of Zepzelca® (lurbinectedin) for the treatment of patients with metastatic Leiomyosarcoma14CNMV
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1